(Modified) U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13425-056002	Application No. 10/618,868
mation Disclosure Statement by Applicant	Applicant Björn Nilsson	
(Use several sheets if necessary)	Filing Date July 14, 2003	Group Art Unit 1614

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
Vb	AA	5,447,931	09/05/1995	Baroni, et al.			

Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes
	AB						

	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner Initial	Desig.	Document
M	AC	Andersson, KE. "Treatment of the overactive bladder: possible central nervous system drug targets." Urology 2002, 59 (Suppl 5A), 18-24.
M	AD	Andersson, K-E: "Pharmacology of penile erection." Pharmacol. Rev. 2001, 53, 417-450.
M	AE	Applegate CD, Tecott, LH. "Global increases in seizure susceptibility in mice lacking 5- HT2C receptors: A behavioural analysis." Exp. Neurol. 1998, 154, 522-530.
W	AF ·	Arjona, A. A.; Pooler, A. M.; Lee, R. K.; Wurtman, R. J. "Effect of a 5-HT(2C) serotonin agonist, dexnorfenfluramine, on amyloid precursor protein metabolism in guinea pigs." Brain. Res. 2002, 951, 135-140.
M	AG	Chojnacka-Wojcik E, Klodzinska A, Deren-Wesolek A. "Involvement of 5-HT2C receptors in the m-CPP-induced antinociception in mice." Pol J Pharmacol. 1994 Sep-Oct;46(5):423-8.
y	АН	Cryan JF, Lucki I "Antidepressant-like behavioral effects mediated by 5-Hydroxytryptamine(2C) receptors." J Pharmacol Exp Ther. 2000 Dec;295(3):1120-6.
NO VOO	AI	de Groat, W.C. "Influence of central serotoneric mechanisms on lower urinary tract function." Urology 2002, 59 (Suppl., 5A), 30-36.
W	AJ	Dhonnchadha BAN, Bourin M, Hascoet M. "Anxiolytic-like effects of 5-HT2 ligands on three mouse models of anxiety." Behavioural Brain Research 2003 140 (1-2): 203-214.
M	AK	Grottick AJ, Corrigall WA, Higgins GA. "Activation of 5-HT(2C) receptors reduces the locomotor and rewarding effects of nicotine." Psychopharmacology (Berl). 2001 Sep; 157(3):292-8.
M	AL	Grottick AJ, Fletcher PJ, Higgins GA. "Studies to investigate the role of 5-HT(2C) receptors on cocaine- and food-maintained behavior." J Pharmacol Exp Ther. 2000 Dec;295(3):1183-91.
M	AM	Guarneri, L. et al. "The effects of m-CPP on bladder voiding contractions in rats are mediated by the 5-HT2A/5-HT2C receptors." Neurourol. Urodyn. 1996, 15, 316-317.
M	AN	Heisler LK, Chu HM, Tecott LH. "Epilepsy and obesity in serotonin 5-HT2C receptor mutant mice." Ann NY Acad Sci 1998, 861, 74-78.
W	AO	Isaac M. "The 5-HT2C receptor as a potential therapeutic target for the design of antiobesity and antiepileptic drugs." Drugs Future 2001, 26, 383-393.
M	AP	Millan, MJ, Peglion, JL, Lavielle G, Perrin-Monneyron S: 5-HT2C receptors mediate penile rections in rats: actions of novel and selective agonists and antagonists." Eur. J. Pharmacol. 1997, 325, 9-12.
M	AQ	Moreau, JL.; Boes, M.; Jenck, F.; Martin, J. R.; Mortas, P.; Wichmann, J. "5HT2C receptor agonists exhibit antidepressant-like properties in the anhedonia model of depression in rats." European Neuropsychopharmacology 1996 6(3), 169-175.

Examiner Signature	Date Considered 7/2 / 8
Examiner Signature V. Balisans amoria	, , ,
EXAMINER: Initials citation considered. Draw line through citation if no next communication to applicant.	t in conformance and not considered. Include copy of this form with
The service of the appropriate of the service of th	Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13425-056002	Application No. 10/618,868	
by A	sciosure Statement pplicant	Appilcant Björn Nilsson		
(Use several sheets if necessary) (37 CFR §1.98(b))		Filing Date July 14, 2003	Group Art Unit 1614	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner	Desig.	
Initial	ID	Document
M	AR	Piesla MJ, Comery TA, Brennan JA, Welmaker GS, Rosenzweig-Lipson S, Marquis KL. "Atypical antipsychotic-like effects of 5-HT2C agonists." Schizophrenia Res. 49 (1-2): 95-95 Sp. lss. SI Suppl. S, APR 15, 2001.
M	AS	Pomerantz SM. "5-HT1A and 5-HT1C/D receptor agonists produce reciprocal effects on male sexual behavior of rhesus monkeys." Eur. J. Pharmacol. 1993, 243, 227-234.
W	AT	Porter, R. H.; Benwell, K. R.; Lamb, H.; Malcolm, C. S.; Allen, N. H.; Revell, D. F.; Adams, D. R.; Sheardown, M. J. "Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells." Br. J. Pharmacol. 1999, 128, 13-20.
M	AU	Pranzatelli, M.R. et al. "Identification of spinal 5-HT1C binding sites in the rat: characterization of [3H]mesulergine binding." J. Pharmacol. Exp. Ther. 1992, 261, 161-165.
M	AV	Steers W.D. et al. "Effects of m-chlorophenylpiperazine on penile and bladder function in rats." Am. J. Physiol. 1989, 257, R1441-R1449.
W	AW	Steers, W.D. et al. "Effects of serotonergic agonists on micturition and sexual function in the rat." Drug Dev. Res. 1992, 27, 361-375.
М	AX	Szele, FG, Murphy DL, Garrick NA: "Effects of fenfluramine, m-chlorophenylpiperazine, and other serotonin-related agonists and antagonists on penile erections in nonhuman primates." Life Sci. 1988, 43, 1297-1303.
M	AY	Tecott, LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, Julius, D. "Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors." Nature 1995, 374, 542-546.
M	AZ	Testa, R. et al. "Effect of different 5-hydroxytryptamine receptor subtype antagonists on the micturition reflex in rats." BJU Int. 2001, 87, 256-264.
M	AAA	Upton N, Stean T, Middlemiss D, Blackburn T, Kennett G. "Studies on the role of 5-HT2C and 5-HT2B receptors in regulating generalized seizure threshold in rodents." Eur. J. Pharmacol. 1998, 359, 33-40.

Examiner Signature	Date Considered
V. Bolesonheurer	1/24/06
EXAMINER: Initials citation considered. Draw line through citation if no	t in conformance and not considered. Include copy of this form with
next communication to applicant.	
	Substitute Disclosure Form (PTO-1449)